BACKGROUND There are over 40000 ischaemic strokes annually in Canada, which result in significant morbidity, mortality and burden to the healthcare system. A recent, large clinical trial has evaluated tissue plasminogen activator (t-PA) intravenously for the treatment of acute ischaemic stroke with promising outcomes but with an increased risk of symptomatic intracranial haemorrhage. OBJECTIV...

Objectives: To describe the prescribing practices, preparation and administration techniques of intrapleural (IP) tissue plasminogen activator (t-PA) and IP DNase in patients at a tertiary academic medical center. Methods: Adult patients receiving IP t-PA and IP DNase between January 1-December 31, 2012 were retrospectively evaluated. Patients were included if they received IP t-PA and/or IP DN...

We study p-adic Euler's series Ep(t)=∑k=0∞k!tk at a point pa, a∈Z≥1, and use Padé approximations to prove lower bound for the absolute value of expression cEp(±pa)−d, where c,d∈Z. It is interesting that same polynomials which p-adically converge Ep(t), approach Hardy integral H(t)=∫0∞e−s1−tsds on Archimedean side. This connection used with trick analytic continuation when deducing an numerator ...

We demonstrated previously that tissue-type plasminogen activator (t-PA) bound to its specific receptor (t-PAR) on human umbilical vein endothelial cells (HUVEC) in suspension and that t-PAR of mol wt. 20 kDa interacted only with t-PA to form 90 kDa complex (Fukao, H., Hagiya, Y., Nonaka, T., Okada, K., and Matsuo, O. (1992) Biochem. Biophys. Res. Commun. 187, 956-962). In the present study, 20...

I ntravenous tissue-type plasminogen activator (t-PA) is an effective treatment for acute ischemic stroke for which efficacy is very time dependent and its greatest benefit occurs with early treatment. 1 Not all patients with ischemic stroke who arrive within 2 to 3 hours after stroke onset are eligible for IV t-PA because they have contraindications, such as recent major surgery , ongoing anti...

BACKGROUND There are more than 300,000 prosthetic heart valve replacements each year worldwide. These patients are faced with a higher risk of thromboembolic events after heart valve surgery and long-term or even life-long anticoagulative and antiplatelet therapies are necessary. Some severe complications such as hemorrhaging or rebound thrombosis can occur when the therapy ceases. Tissue-type ...

Smooth muscle cells (SMCs) in balloon-injured rat carotid artery express tissue-type plasminogen activator (t-PA) at a time when they are migrating from the media to the intima. Since heparin inhibits SMC migration and intimal thickening, we have examined the possibility that heparin might also inhibit t-PA expression. Heparin (nonanticoagulant fraction; molecular weight, approximately 6,000) w...